Medically Reviewed by 23C Regen Clinical Advisory Board
Fatty liver disease is increasingly common in Malaysia, closely tied to rising rates of obesity, type 2 diabetes, and metabolic syndrome. Many people discover they have it incidentally, through a routine ultrasound or blood test, with no symptoms at all. This guide explains current terminology, how risk is assessed, what standard management looks like, and what current regenerative research can and cannot currently offer for this specific condition.
Understanding MASLD Terminology
If you’ve researched fatty liver disease before, you may have come across several different, sometimes confusing, terms. Medical terminology in this area has shifted in recent years toward more precise language.
| Term | What It Means |
| NAFLD (Non-Alcoholic Fatty Liver Disease) | Older terminology, still widely used and understood |
| MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease) | Updated, preferred terminology reflecting the metabolic basis of the condition |
| MASH (Metabolic dysfunction-Associated Steatohepatitis) | A more advanced form involving liver inflammation and cell damage, previously called NASH |
| Simple steatosis | Fat accumulation in the liver without significant inflammation or damage |
This terminology shift isn’t just academic, it reflects a clearer understanding that fatty liver disease is fundamentally linked to metabolic health, insulin resistance, obesity, and related conditions, rather than being a standalone liver problem.
Fatty Liver Disease Risk Assessment
Fatty liver disease doesn’t develop in isolation. It’s strongly associated with a cluster of metabolic risk factors common in the Malaysian population.
Key risk factors include:
- Overweight or obesity, particularly central/abdominal obesity
- Type 2 diabetes or insulin resistance
- High triglycerides or abnormal cholesterol levels
- High blood pressure
- Metabolic syndrome (a combination of the above factors)
- Sedentary lifestyle and diet high in processed foods and sugar
How risk and severity are typically assessed:
- Liver function blood tests, though these can appear normal even with significant fatty liver present
- Ultrasound imaging, commonly the first-line tool to detect fat accumulation in the liver
- FibroScan (transient elastography), assessing both fat content and liver stiffness, which helps estimate scarring (fibrosis) risk
- Blood-based fibrosis scoring tools (such as FIB-4), used to help estimate risk of more advanced liver scarring
- Liver biopsy, reserved for cases where more definitive staging is needed
Standard Management of Fatty Liver Disease
Management of fatty liver disease centres almost entirely on addressing the underlying metabolic drivers, since there is currently no medication universally approved specifically to reverse the condition.
| Approach | Purpose |
| Weight loss (gradual, sustained) | The single most effective intervention; even 7–10% body weight loss can meaningfully reduce liver fat |
| Dietary changes | Reducing refined sugar, processed food, and excess calorie intake |
| Regular physical activity | Improves insulin sensitivity and supports weight management |
| Managing diabetes and cholesterol | Treating underlying metabolic conditions directly |
| Limiting alcohol | Reduces additional liver stress, even in non-alcohol-related fatty liver |
| Emerging medications | Certain newer medications are being studied and, in some cases, approved for more advanced forms (MASH) in select markets |
Joint pain is a common reason people struggle to stay active, and for those with knee problems, non-surgical alternatives to knee replacement, such as physiotherapy and weight management, can make regular movement far easier.
Monitoring Fatty Liver Disease Assessment
Because fatty liver disease can progress silently through fibrosis toward cirrhosis, or, in a smaller proportion of cases, to liver cancer, ongoing monitoring matters even when you feel completely well.
Typical monitoring includes:
- Periodic liver function tests, usually every 6 to 12 months depending on risk level
- Repeat imaging or FibroScan, to track changes in liver fat and stiffness over time
- Metabolic monitoring, including blood sugar, lipid profile, and weight trends
- Reassessment of fibrosis risk scores periodically, particularly if risk factors change
Monitoring frequency should be individualised based on your specific risk factors and findings, ideally guided by a hepatologist or physician familiar with your full history. Because the same metabolic conditions behind fatty liver, such as diabetes and high blood pressure, can also affect the kidneys, kidney checks like eGFR and urine albumin (UACR) tests often sit alongside the liver review. And if testing points to advanced scarring, monitoring may expand to include liver cancer risk screening.
When to See a Hepatologist
Not every fatty liver finding requires specialist referral, but certain signs suggest it’s time to see a hepatologist rather than continuing with general monitoring alone:
- Elevated or rising liver enzymes on repeat testing
- A FibroScan or fibrosis score indicating significant scarring risk
- Known MASH (inflammation-related fatty liver) rather than simple steatosis
- Coexisting viral hepatitis or other liver conditions
- A family history of liver disease or liver cancer
- Any symptoms suggesting more advanced liver involvement, such as unexplained fatigue, abdominal discomfort, or jaundice
Early specialist input, before the condition progresses to cirrhosis, generally offers the most options for effectively managing the disease course. If advanced fibrosis is confirmed, your hepatologist may also recommend regular ultrasound checks for liver cancer, since scarring is what raises that risk.
Role and Limits of Research
Regenerative medicine research, including mesenchymal stem cell studies, has begun exploring fatty liver disease and its more advanced form, MASH, largely in preclinical and very early clinical settings.
What early research is exploring:
- Potential anti-inflammatory and metabolic effects of MSCs in liver tissue models
- Whether cell-based approaches might support a healthier liver environment alongside standard metabolic management
What current evidence does not establish:
- No regulatory authority has approved stem cell therapy specifically for fatty liver disease or MASH
- There is no established evidence that stem cell therapy reverses fat accumulation or fibrosis in this condition
- Lifestyle and metabolic management remain the only well-established, evidence-backed interventions at this time
23C Regen’s current treatable conditions list centres on more established research areas such as liver cirrhosis, where more clinical evidence exists. If you have early-stage fatty liver disease, the most valuable next step is usually metabolic risk management and monitoring, discussed below, rather than a cell therapy assessment.
Why Early Action Matters in Fatty Liver Disease
Fatty liver disease sits at a genuinely useful decision point. Caught and addressed early, through weight management, dietary change, and treatment of underlying metabolic conditions, it can often improve significantly or even resolve. Left unaddressed over years, particularly if it progresses to MASH with ongoing inflammation, it can advance toward fibrosis and eventually cirrhosis, a stage that is far harder to reverse. This is really the core message worth taking from current evidence: the most valuable intervention available right now for fatty liver disease isn’t a procedure or emerging therapy, it’s consistent, sustained metabolic management, started as early as possible.
Questions Worth Discussing With Your Doctor before Fatty Liver Disease Assessment
- What stage is my fatty liver disease at, and how was that determined?
- What specific, achievable lifestyle changes would make the most difference for me?
- How often should I be monitored, given my individual risk factors?
- Do I need a referral to a hepatologist at this stage?
- Is regenerative research relevant to my situation currently, or is lifestyle management the appropriate focus for now?
If you’d like to discuss your liver health more broadly, including whether an assessment for related conditions such as cirrhosis may be relevant to your situation, you’re welcome to get in touch.
Fatty Liver Disease Management & Care in Malaysia
Managing fatty liver disease recently classified under metabolic and lifestyle-driven criteria like MAFLD (Metabolic Dysfunction-Associated Fatty Liver Disease) requires a focused approach tailored to the Malaysian population. Given the high prevalence of metabolic risk factors such as type 2 diabetes, central obesity, and dyslipidemia locally, early detection and proactive lifestyle adjustments are vital to halting liver inflammation and preventing long-term fibrosis.
Navigating Fatty Liver Care & Treatment Protocols in Malaysia
- Early Screening & Diagnostic Evaluation: Utilizing routine liver function tests (LFTs), lipid profiles, and non-invasive assessment tools like FibroScan (ultrasound-based liver stiffness measurement) helps detect hepatic fat accumulation before symptoms progress.
- Targeted Lifestyle & Weight Management: Achieving a gradual body weight reduction of 5% to 10% through a balanced, low-calorie diet and increased physical activity significantly decreases intrahepatic fat and lowers inflammation.
- Managing Underlying Metabolic Risk Factors: Controlling blood glucose levels, managing hypertension, and regulating cholesterol are crucial steps supported by clinical consensus guidelines from the Malaysian Society of Gastroenterology and Hepatology (MSGH).
- Dietary Adjustments Tailored to Local Cuisine: Modifying traditional Malaysian dietary patterns by reducing refined carbohydrates, sugary beverages, and hidden saturated fats helps alleviate metabolic stress on the liver.
- Evidence-Based Medical Supervision: Working alongside registered gastroenterologists and hepatologists ensures that any interventions align strictly with evidence-based clinical practices available across private and public healthcare facilities in Malaysia.
Guides on this topic
- Is fatty liver reversible?
- Fatty liver diet: a Malaysian food guide
- FibroScan fatty liver testing in Malaysia
- Fatty liver stages: from fibrosis to cirrhosis
- How to lower liver cancer risk in Malaysia
- High ALT and AST: what your liver test means
Frequently Asked Questions
Is fatty liver disease the same as liver cirrhosis?
No. Fatty liver disease is an earlier, often reversible stage. Cirrhosis is advanced, usually permanent scarring that can develop if fatty liver disease progresses untreated over years.
Can fatty liver disease be reversed?
Simple fatty liver (steatosis) can often improve significantly with sustained weight loss and lifestyle changes. More advanced fibrosis is harder to reverse.
Do I need a biopsy to diagnose fatty liver disease?
Not usually. Ultrasound and FibroScan are commonly used first, with biopsy reserved for cases needing more definitive staging or diagnosis.
Is stem cell therapy available for fatty liver disease at 23C Regen?
Not currently as a standard offering. Evidence in this specific condition remains early-stage; our established programmes focus on more researched areas like cirrhosis.
How much weight loss is needed to improve fatty liver disease?
Research suggests even 7–10% sustained body weight loss can meaningfully reduce liver fat and improve related metabolic markers in many patients.
Can I have fatty liver disease without being overweight?
Yes, it can occur in people of normal weight, particularly with insulin resistance or other metabolic risk factors, though it’s more common with excess weight.
Speak With Our Team About Your Liver Health
If you’ve been told you have fatty liver disease, or you’re unsure what your scan or blood results mean, bring your recent liver function tests, ultrasound or FibroScan reports, and metabolic results to a consultation. Our team can talk you through where you stand and what current evidence does and doesn’t support for your situation.










